Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312718 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Keith M Gunapala und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland. Hauptthemen laut MEDLINE: Fragile X Syndrome, Induced Pluripotent Stem Cells, Organoids, Ascorbic Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Botnar, Basel Research Centre for Child Health, Azrieli Foundation.
Abstract (Originalsprache)
Fragile X Syndrome (FX) is the most common form of inherited cognitive impairment and falls under the broader category of Autism Spectrum Disorders (ASD). FX is caused by a CGG trinucleotide repeat expansion in the non-coding region of the X-linked Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene, leading to its hypermethylation and epigenetic silencing. Animal models of FX rely on the deletion of the Fmr1 gene, which fails to replicate the epigenetic silencing mechanism of the FMR1 gene observed in human patients. Human stem cells carrying FX repeat expansions have provided a better understanding of the basis of epigenetic silencing of FMR1. Previous studies have found that 5-Azacytidine (5Azac) can reverse this methylation; however, 5Azac can be toxic, which may limit its therapeutic potential. Here, we show that the dietary factor Ascorbic Acid (AsA) can reduce DNA methylation in the FMR1 locus and lead to an increase in FMR1 gene expression in FX iPSCs and cerebral organoids. In addition, AsA treatment rescued neuronal gene expression and morphological defects observed in FX iPSC-derived cerebral organoids. Hence, we demonstrate that the dietary co-factor AsA can partially revert the molecular and morphological defects seen in human FX models in vitro. Our findings have implications for the development of novel therapies for FX in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
- The Azrieli Center for Stem Cells and Genetic Research, Department of Genetics, Institute of Life Sciences, The Hebrew University, Jerusalem 91904, Israel.
- Swiss Institute of Bioinformatics, 4031 Basel, Switzerland.
ORCID-Profile: Keith M Gunapala, Faiza Noreen, Verdon Taylor
Förderung
- Fondation Botnar
- Basel Research Centre for Child Health
- Azrieli Foundation
- Israel Science Foundation
- Rosetrees Trust
- ISF-Israel Precision Medicine Partnership (IPMP) Program
Zitieren
APA
Gunapala, K. M., Gadban, A., Noreen, F., Schär, P., Benvenisty, N., & Taylor, V. (2024). Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312718
Vancouver
Gunapala KM, Gadban A, Noreen F, Schär P, Benvenisty N, Taylor V. Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312718
BibTeX
@article{Gunapala2024,
author = {Gunapala, Keith M and Gadban, Aseel and Noreen, Faiza and Schär, Primo and Benvenisty, Nissim and Taylor, Verdon},
title = {Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312718}
}
EUVIMED